IL153236A0 - The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders - Google Patents

The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Info

Publication number
IL153236A0
IL153236A0 IL15323601A IL15323601A IL153236A0 IL 153236 A0 IL153236 A0 IL 153236A0 IL 15323601 A IL15323601 A IL 15323601A IL 15323601 A IL15323601 A IL 15323601A IL 153236 A0 IL153236 A0 IL 153236A0
Authority
IL
Israel
Prior art keywords
copolymer
treatment
nervous system
central nervous
system disorders
Prior art date
Application number
IL15323601A
Other languages
English (en)
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of IL153236A0 publication Critical patent/IL153236A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15323601A 2000-06-05 2001-06-05 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders IL153236A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58752300A 2000-06-05 2000-06-05
PCT/US2001/018248 WO2001093828A1 (en) 2000-06-05 2001-06-05 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Publications (1)

Publication Number Publication Date
IL153236A0 true IL153236A0 (en) 2003-07-06

Family

ID=24350145

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15323601A IL153236A0 (en) 2000-06-05 2001-06-05 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders

Country Status (9)

Country Link
EP (1) EP1292279A4 (de)
JP (1) JP2003535118A (de)
AU (2) AU7528001A (de)
CA (1) CA2411536A1 (de)
HU (1) HUP0302333A3 (de)
IL (1) IL153236A0 (de)
PL (1) PL363431A1 (de)
WO (1) WO2001093828A1 (de)
ZA (1) ZA200210084B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
US7022663B2 (en) 2000-02-18 2006-04-04 Yeda Research And Development Co., Ltd. Oral, nasal and pulmonary dosage formulations of copolymer 1
US20020077278A1 (en) 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
WO2002076503A1 (en) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Treatment of central nervous system diseases by antibodies against glatiramer acetate
ATE475883T1 (de) 2001-12-04 2010-08-15 Teva Pharma Verfahren zur messung der wirkstärke von glatirameracetat
WO2006029411A2 (en) 2004-09-09 2006-03-16 Yeda Research And Development Co. Ltd. Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof
EA019998B9 (ru) 2009-08-20 2016-01-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Терапия глатирамером ацетатом с низкой кратностью
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
US8709433B2 (en) 2010-10-11 2014-04-29 Teva Pharmaceutical Industries Ltd. Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate
CA2851510A1 (en) 2011-10-10 2013-04-18 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CA2884267A1 (en) 2012-10-10 2014-04-17 Teva Pharmaceutical Industries Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US10166253B2 (en) 2014-08-29 2019-01-01 Region Midtjylland Positively charged co-polymers for use as antimicrobial agents
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
CN106924175B (zh) * 2015-12-29 2020-07-03 深圳翰宇药业股份有限公司 一种治疗多发性硬化症的药物组合物
WO2017201539A1 (en) 2016-05-20 2017-11-23 Cedars-Sinai Medical Center Methods of treating or preventing alzheimer's disease and associated conditions
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
GB9411292D0 (en) * 1994-06-06 1994-07-27 Teva Pharma Pharmaceuticals compositions
US5665764A (en) * 1995-06-02 1997-09-09 Warner-Lambert Company Tricyclic inhibitors of matrix metalloproteinases
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
JP4328050B2 (ja) * 2000-01-20 2009-09-09 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用
ATE314860T1 (de) * 2000-06-07 2006-02-15 Yeda Res & Dev Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet

Also Published As

Publication number Publication date
AU7528001A (en) 2001-12-17
JP2003535118A (ja) 2003-11-25
PL363431A1 (en) 2004-11-15
AU2001275280B2 (en) 2006-03-16
EP1292279A1 (de) 2003-03-19
WO2001093828A1 (en) 2001-12-13
EP1292279A4 (de) 2005-01-12
HUP0302333A2 (hu) 2003-11-28
CA2411536A1 (en) 2001-12-13
ZA200210084B (en) 2003-12-12
HUP0302333A3 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
IL153236A0 (en) The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
HUP0100069A3 (en) 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
HK1046274A1 (en) Spiro Ä1-azabicycloÄ2.2.2.Üoctane-3,2'(3'h)-furoÄ2,3-bÜpyridine for use in the treatment of psychotic and intellectual impairment disorders.
AU9112201A (en) Pulmonary delivery in treating disorders of the central nervous system
HUP0100786A3 (en) Substituted 2-phenyl-1-(3,4-dihydroxy-5-nitrophenyl)-1-ethanones, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
IL151946A0 (en) 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders
HUP0401023A3 (en) Use of flibanserin in the treatment of sexual disorders
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
ZA97741B (en) Pharmaceutical combined preparation and its use in the treatment of gynaecological disorders.
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
HUP0204050A3 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
IL160018A0 (en) Isoxazolopyridinones and use thereof in the treatment of parkinson's disease
HK1062811A1 (en) Chemokine mutants in the treatment of multiple sclerosis
EP1079764A4 (de) Behandlung sexueller störungen bei bestimmten patientengruppen
GB0015228D0 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
HUP0301553A3 (en) Pharmaceutical compositions and their use for treating neurological disorders
AU2002226060A1 (en) Compositions containing gangliosides for use in the treatment of skin disorders
IL129460A0 (en) Use of lofexidine in the treatment of behavioral disorders
AU5963396A (en) Cis-resorcylide, pharmaceutical composition containing it, use thereof in the treatment of thrombosis and related disorders
AU2002210763A1 (en) Use of 1-ebio in the treatment of bipolar disorders
AU6330300A (en) Use of interleukin-6 in treatment of obesity and/or obesity associated disorders
AU2001292500A1 (en) 1,2,5,10-tetrahydropyridazino(4,5-b)quinoline-1,10-diones and their use for the treatment of pain